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1 INTRODUCTION
In many studies involving the comparison of survival data from two treatment groups, a mark
variable is measured only in failures, and it is of interest to account for this mark in comparing
the failure experience. In this article, we develop testing and estimation procedures to assess
mark-specifi c relative risks. Our approach is based on recent work in which we developed a test
for the dependence of a single mark-specifi c hazard rate on the mark variable (i.e., the “one-
sample” problem, Gilbert, McKeague and Sun, 2004).
We are motivated by applications in HIV vaccine effi cacy trials. The extensive genetic diver-
sity of HIV poses one of the greatest challenges to developing an AIDS vaccine (Graham 2002).
Vaccine effi cacy to prevent infection, usually defi ned in terms of the hazard ratio between vaccine
and placebo recipients, may decrease with the viral divergence of a challenge HIV from the virus
or viruses represented in the vaccine construct (Gilbert, Lele and Vardi, 1999). Detecting such a
decrease can help guide the development of new vaccines to provide greater breadth of protec-
tion (Gilbert et al., 2001). The relevance of our mark-specifi c hazard function approach is that
the “distance” between a subject’s infecting strain and the nearest vaccine strain can be viewed
as a mark variable that is only observed in subjects who experience the event (HIV infection).
From 1998 to 2003 VaxGen Inc. conducted the world’s fi rst HIV vaccine effi cacy trial (Flynn
et al., 2005). HIV uninfected volunteers at high risk for acquiring HIV were randomized to
receive the vaccine AIDSVAX (n1 = 3, 598) or placebo (n2 = 1, 805). Subjects were monitored
for 3 years for the primary study endpoint HIV infection. For each subject who became HIV
infected, the envelope glycoprotein (gp120) region of the infecting virus was sequenced. Of the
368 subjects who acquired HIV, the sequence data were collected for 336 subjects (217 of 241
vaccine; 119 of 127 placebo). VaxGen hypothesized that the level of vaccine effi cacy would be
higher against HIVs with gp120 amino acid sequences that were relatively similar to either of the
two HIV strains (named MN and GNE8) that were represented in the vaccine. The distance of
each infecting virus to MN and to GNE8 was measured by the percent mismatch in the aligned
amino acid sequences (i.e., Hamming distance) for three sets of positions hypothesized to be
important for neutralizing HIV (Wyatt et al., 1998): (1) the neutralizing face core of gp120 that
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was crystalized; (2) the neutralizing face core plus the variable loop V2/V3 regions; and (3) the
V3 loop. For each metric and infecting virus, the mark is defi ned as the minimum of the two
distances to the MN and GNE8 reference sequences.
Gilbert, Lele and Vardi (1999) and Gilbert (2000) developed a semiparametric biased sam-
pling model as a tool for studying vaccine effi cacy as a function of a continuous mark, which
parametrically specifi es the relationship between vaccine effi cacy and the mark, and leaves the
distribution of the mark in the infected placebo group unspecifi ed. However, there are no data
available for suggesting the correct parametric model, so nonparametric methods are desirable.
Furthermore, the earlier work is limited by conditioning on infection, so odds ratios but not rela-
tive risks of infection can be estimated, and the model treats HIV infection as a binary outcome,
ignoring the time to HIV infection. The methods presented here were developed because they
are free from these limitations, as they are nonparametric (though semiparametric procedures are
also considered), prospective, and incorporate the failure times.
We introduce tests for the hypothesis that the mark-specifi c risks in the two groups coincide,
and for the hypothesis that the relative mark-specifi c risk between the groups is independent
of the mark. The time Tk to endpoint and the mark variable Vk for a representative individual in
group k are assumed to be jointly absolutely continuous with joint density fk(t, v). We only get to
observe (Xk, δk, δkVk), where Xk = min{Tk, Ck}, δk = I(Tk ≤ Ck), and Ck is a censoring time
assumed to be independent of both Tk and Vk, k = 1, 2. When the failure time Tk is observed,
δk = 1 and the mark Vk is also observed, whereas if Tk is censored, the mark is unknown. Since
the mark is only observed for failures, it cannot be studied as a covariate in evaluating risk. We
assume that each mark variable Vk has known and bounded support; rescaling Vk if necessary,
this support is taken to be [0, 1]. The mark-specifi c hazard rate in group k is
λk(t, v) = lim
h1,h2→0
P{Tk ∈ [t, t + h1), Vk ∈ [v, v + h2)|Tk ≥ t}/h1h2 (1.1)
and the mark-specifi c cumulative incidence function is
Fk(t, v) = lim
h2→0
P{Tk ≤ t, Vk ∈ [v, v + h2)}/h2, (1.2)
k = 1, 2, with t ranging over a fi xed interval [0, τ ]. The functions (1.1) and (1.2) are related by
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the equation Fk(t, v) =
∫ t
0
λk(s, v)Sk(s) ds, where Sk(t) is the survival function for group k,
and are estimable from the observed group k competing risks failure time data. In the case of
a discrete mark variable, Gray (1988) developed a nonparametric test for comparing cumulative
incidence functions among groups, at a specifi ed value of the mark variable.
A standard measure of vaccine effi cacy to prevent infection at time t is the relative reduction
in hazard due to vaccination: VE(t) = 1 − λ1(t)/λ2(t), see Halloran, Struchiner, and Longini
(1997). It is natural to extend this defi nition to allow the vaccine effi cacy to depend on viral
divergence: VE(t, v) = 1 − λ1(t, v)/λ2(t, v). Under the assumption of an equal distribution of
exposure to HIV strains with divergence v for vaccine and placebo recipients at all times up to
t (defensible by randomization and double-blinding), VE(t, v) approximately equals the relative
multiplicative reduction in susceptibility to strain v for vaccine versus placebo recipients under a
fi xed amount of exposure to strain v at time t.
To account for the mark in testing for vaccine effi cacy, we develop tests for the null hypothesis
H00 : λ1(t, v) = λ2(t, v) for (t, v) ∈ [0, τ ]× [0, 1]
against the following alternative hypotheses:
H01 : λ1(t, v) ≤ λ2(t, v) for all (t, v) ∈ [0, τ ]× [0, 1];
H02 : λ1(t, v) 6= λ2(t, v) for some (t, v) ∈ [0, τ ]× [0, 1]
with strict inequality for some (t, v) ∈ [0, τ ] × [0, 1] in H01 . The objective of testing H00 is to
assess if there is vaccine effi cacy against any HIV strain, and as we show in simulations can
provide much greater power than standard tests of vaccine effi cacy that ignore the mark.
If H00 is rejected, then it is of interest to assess if vaccine effi cacy varies with strain distance.
Accordingly, we also develop tests for
H0: λ1(t, v)/λ2(t, v) does not depend on v for t ∈ [0, τ ]
against the following alternative hypotheses:
H1: λ1(t, v1)/λ2(t, v1) ≤ λ1(t, v2)/λ2(t, v2) for all v1 ≤ v2, t ∈ [0, τ ];
H2: λ1(t, v1)/λ2(t, v1) 6= λ1(t, v2)/λ2(t, v2) for some v1 ≤ v2, t ∈ [0, τ ]
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with strict inequality for some t, v1, v2 in H1. To develop suitable test statistics, we will exploit the
observation that H0 holds if and only if the mark-specifi c relative risk coincides with the ordinary
relative risk, i.e., λ1(t, v)/λ2(t, v) = λ1(t)/λ2(t) for all t, v, where λk(t) =
∫ 1
0
fk(t, v) dv/Sk(t) =∫ 1
0
λk(t, v) dv is the group-k hazard irrespective of the mark.
Testing H0 versus H1 allows us to assess whether the instantaneous relative risk of HIV
infection for vaccine versus placebo recipients increases as a function of the divergence v of the
exposing virus. These hypotheses can be re-expressed as H0 : VE(t, v) = VE(t) for all t, v;
H1 : VE(t, v1) ≤ VE(t, v2) for all t, v1 ≥ v2 (with < for some v1 > v2); and H2 : VE(t, v1) 6=
VE(t, v2) for some t, v1 6= v2.
In Section 2 we introduce the proposed procedures for testing H 00 and H0. Large sample
results and a simulation technique needed to implement the test procedures are developed in
Section 3. In Section 4 we discuss nonparametric estimation of the mark-specifi c vaccine effi cacy.
We report the results of a simulation experiment in Section 5, and an application to data from the
VaxGen trial is provided in Section 6. Section 7 contains concluding remarks. Proofs of the main
results are collected in the Appendix.
2 TEST PROCEDURE
We base our approach on estimates of the doubly cumulative mark-specifi c hazard functions
Λk(t, v) =
∫ v
0
∫ t
0
λk(s, u) ds du, k = 1, 2. Given observation of i.i.d. replicates (Xki, δki, δkiVki), i =
1, . . . , nk, of (Xk, δk, δkVk), k = 1, 2, the nonparametric maximum likelihood estimator (MLE)
of Λk(t, v) is provided by the Nelson–Aalen-type estimator
Λˆk(t, v) =
∫ t
0
Nk(ds, v)
Yk(s)
, t ≥ 0, v ∈ [0, 1], (2.1)
where Yk(t) =
∑nk
i=1 I(Xki ≥ t) is the size of the risk set for group k at time t, and
Nk(t, v) =
nk∑
i=1
I(Xki ≤ t, δki = 1, Vki ≤ v)
is the marked counting process with jumps at the uncensored failure times Xki and associated
marks Vki, see Huang and Louis (1998, (3.2)).
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Our tests of H00 are based on comparing Λˆ1(t, v) and Λˆ2(t, v), and of H0 are based on compar-
ing the nonparametric MLE of Λ1(t, v)−Λ2(t, v) with an estimate under H0. Since H0 is equiva-
lent to Λ1(t, v) =
∫ t
0
[λ1(s)/λ2(s)]Λ2(ds, v) for all t, v, under H0 we may estimate the difference
Λ1(t, v)− Λ2(t, v) by
∫ t
0
[(λˆ1(s)/λˆ2(s))− 1]Λˆ2(ds, v), where λˆk(t) is a nonparametric estimator
of λk(t), as discussed below. Alternatively, under a proportional marginal hazards assumption,
λ1(t)/λ2(t) = exp(β), this difference may be estimated by
∫ t
0
[exp(βˆ) − 1]Λˆ2(ds, v), where βˆ
is the maximum partial likelihood estimator of β, which leads to a semiparametric test for H0.
The nonparametric approach makes minimal assumptions but requires smoothing, whereas the
semiparametric approach avoids smoothing and in principle may provide greater power when the
proportional hazards assumption holds.
For the nonparametric approach we estimate each hazard function λk(t) by kernel smoothing:
λˆk(t) =
1
bk
∫ τ+δ
0
K
(
t− s
bk
)
dΛˆk(s) ,
where Λˆk(s) =
∫ t
0
(1/Yk(s)) dNk(s) is the Nelson–Aalen estimator of Λk(t) =
∫ t
0
λk(s) ds,
with Nk(t) =
∑nk
i=1 I(Xki ≤ t, δki = 1). The kernel K is a bounded symmetric function with
support [−1, 1] and integral 1. The bandwidth bk is a positive parameter that indicates the window
[t − bk, t + bk] over which Λˆk(t) is smoothed, and converges to zero as nk → ∞. We choose
kernel esimators because they are uniformly consistent under assumptions (see Theorem IV.2.2
in Andersen et al., 1993), a property that is needed for the theoretical justifi cation given later.
2.1 Test Processes and Test Statistics
Based on the above discussion, we introduce test processes of the form
Lrn(t, v) =
√
n1n2
n
∫ t
a
Hn(s)
[
Λˆ1(ds, v)− rˆ(s)Λˆ2(ds, v)
]
(2.2)
for t ≥ 0, 0 ≤ v ≤ 1, where Hn(·) is a suitable weight process converging to a non-random func-
tion H(·) and a ≥ 0. The superscript r reflects the choice of process rˆ(s) in the test process and
indicates whether it is used to test H00 (indicated by r as 1, corresponding to rˆ(s) = 1), to test H0
nonparametrically (indicated by r as np; rˆ(s) = λˆ1(s)/λˆ2(s)) or to test H0 semiparametrically
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(indicated by r as sp; rˆ(s) = exp(βˆ)). A simple calculation shows that for r as np (r as sp), [·] in
(2.2) compares Λˆ1(ds, v)− Λˆ2(ds, v) to the nonparametric (semiparametric) estimate described
above of Λ1(ds, v)− Λ2(ds, v) under H0.
A variety of test statistics can be formulated as functionals of Lrn(t, v). We develop integration
type and supremum type statistics. With wV (v) a known nonnegative weight function, large
values of the following test statistics provide evidence against H 00 in the direction of H10 (fi rst
two statistics) or H20 (second two statistics):
Uˆ11 = L
1
n(τ, 1), Uˆ
1
2 =
∫ 1
0
wV (v)L
1
n(τ, v)dv, (2.3)
Uˆ13 = |L1n(τ, 1)|, Uˆ14 =
∫ 1
0
wV (v)(L
1
n(τ, v))
2dv. (2.4)
For testing H0, let yk(t) = P (Xk ≥ t), let τ˜ = sup{t: y1(t) > 0 and y2(t) > 0}, and assume
τ < τ˜ . With kernel smoothing, the bias term of λˆk(t) is of order O(b2k) for the inner points in
[bk, τ˜ − bk] and of order O(bk) for the boundary points in (0, bk) or (τ˜ − bk, τ˜). To simplify the
proofs and the conditions on the rates of convergence concerning bk, we take a > 0 and construct
the test statistics from the process Lrn(t, v) over a ≤ t ≤ τ, 0 ≤ v ≤ 1. In practice, however,
there would be no harm in taking a = 0 in order to use as much of the data as possible (this is
done in the simulations and application).
Set ∆rn(t, v1, v2) = Lrn(t, v1)+Lrn(t, v2)−2Lrn(t, (v1+v2)/2). For r as np or sp, the following
test statistics measure departures from H0 in the direction of H1 (Uˆ r1 ) or H2 (Uˆ r2 ):
Uˆ r1 = sup
v1<v2
sup
0≤t1<t2<τ
[∆rn(t2, v1, v2)−∆rn(t1, v1, v2)] , (2.5)
Uˆ r2 = sup
v1<v2
sup
0≤t1<t2<τ
|∆rn(t2, v1, v2)−∆rn(t1, v1, v2)| . (2.6)
To motivate the test statistics Uˆ r1 and Uˆ r2 , we note from the proof of Theorem 2 in the Ap-
pendix that (n/n1n2)1/2[∆rn(t2, v1, v2)−∆rn(t1, v1, v2)] converges in probability to δ(t1, t2, v1, v2) =∫ t2
t1
∫ v2
v1+v2
2
H(s)(λ1(s, v)− r(s)λ2(s, v)) dv ds−
∫ t2
t1
∫ v1+v2
2
v1
H(s)(λ1(s, v)− r(s)λ2(s, v)) dv ds,
where r(s) = λ1(s)/λ2(s) or exp(β). Under H0, δ(t1, t2, v1, v2) = 0 for all t1, t2 ∈ [0, τ ]
and v1, v2 ∈ [0, 1]. Under H1 and some smoothness conditions, δ(t1, t2, v1, v2) > 0 for some
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t1 < t2 ∈ [0, τ ] and v1 < v2 ∈ [0, 1]. Therefore large values of Uˆ r1 (Uˆ r2 ) provide evidence against
H0 in the direction of H1 (H2).
In the next section, we provide results that all three processes Lrn(t, v) (indexed by r) converge
weakly to a Gaussian process under the appropriate null hypothesis. We also state results (with
proofs given in the Appendix) on the consistency of the proposed tests against their alternatives,
and describe a simulation procedure for determining the critical values of the Uˆ rj .
3 LARGE-SAMPLE RESULTS
We present the asymptotic results for the nonparametric tests of H0. Parallel results for the
semiparametric tests of H0 and the tests of H00 follow by similar but simplifi ed arguments; these
results are briefly stated at the end of this section.
We begin by defi ning notation that is used in the sequel. Let γk(t, v) = P (Xk ≤ t, δk =
1, Vk ≤ v), k = 1, 2. By the Glivenko–Cantelli Theorem, Nk(t, v)/nk and Yk(t)/nk converge
almost surely to γk(t, v) and yk(t), uniformly in (t, v) ∈ [0,∞) × [0, 1] and t ∈ [0,∞), re-
spectively. Note that we may write λk(t, v) = fk(t, v)/STk(t), where STk(t) = P (Tk ≥ t) and
fk(t, v) is the joint density of (Tk, Vk) for group k. Also λk(t) = fTk(t)/STk(t), where fTk(t) is
the density of Tk for group k. Let D(I) be the set of all uniformly bounded, real-valued functions
on a K-dimensional rectangle I , endowed with the uniform metric. Let C(I) be the subspace of
uniformly bounded, continuous functions on I .
3.1 Asymptotic Distributions of the Test Statistics
Let Z1(t, v) and Z2(t, v) be two independent Gaussian processes defi ned by
Zk(t, v) =
∫ t
0
1
yk(s)
G
(k)
1 (ds, v)−
∫ t
0
G
(k)
2 (s)
yk(s)2
γk(ds, v), k = 1, 2, (3.1)
where G(k)1 (t, v) and G
(k)
2 (t) are continuous mean zero Gaussian processes with covariances
Cov(G
(k)
1 (s, u), G
(k)
1 (t, v)) = γk(s ∧ t, u ∧ v)− γk(s, u)γk(t, v),
8
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Cov(G
(k)
2 (s), G
(k)
2 (t)) = yk(s ∨ t)− yk(s)yk(t),
Cov(G
(k)
1 (s, u), G
(k)
2 (t)) = (γk(s, u)− γk(t−, u))I(t ≤ s)− γk(s, u)yk(t).
Let a(t) = 1/λ2(t) and 0 < κ = limn→∞ n1/n < 1. Defi ne
Lnp(t, v) =
√
1− κ
[∫ t
a
H(s)Z1(ds, v)−
∫ t
a
H(s)a(s)Λ′2s(s, v) Z1(ds, 1)
]
−√κ
[∫ t
a
H(s)r(s)Z2(ds, v)−
∫ t
a
H(s)r(s)a(s)Λ′2s(s, v) dZ2(ds, 1)
]
,(3.2)
where Λ′2t(t, v) = ∂Λ2(t, v)/∂t.
Our fi rst result describes the limiting null distribution of the test process and the test statistics.
Theorem 1. Suppose Hn(t) is a continuous functional of the processes Nk(t, 1) and Yk(t), k =
1, 2, t ∈ [0, τ +δ], τ +δ < τ˜ for some δ > 0. Assume there exists a uniformly continuous function
H(t) such that sup0≤t≤τ+δ |Hn(t) − H(t)| a.s.−→0 and both Hn and H have bounded variation
independent of n almost surely. Assume λk(t) is twice continuously differentiable over [0, τ +
δ], k = 1, 2, λ2(t) is bounded away from zero on [a/2, τ + δ], λ2(t, v) > 0 and ∂2Λ2(t, v)/∂t2 is
continuous on [0, τ + δ] × [0, 1]. Also assume the kernel function K(·) has bounded variation.
Suppose nb2k →∞ and nb6k → 0 for k = 1, 2. Then, under H0
Lnpn (t, v)
D−→Lnp(t, v) in D([a, τ ]× [0, 1]) as n →∞. (3.3)
The proof of Theorem 1 immediately follows from Proposition 1 given in the Appendix. The
conditions on the rates of convergence are satisfi ed if bk = n−αk for 1/6 < α < 1/2.
Let U rj be defi ned the same asUˆ rj in (2.5)-(2.6), with Lrn(t, v) replaced with Lr(t, v). By the
continuous mapping theorem, Uˆnpj
D−→Unpj under H0, so P (Uˆnpj > cjα) → α, where cjα is the
upper α-quantile of Unpj . However, the cjα are unknown and very diffi cult to estimate due to the
complicated nature of the limit process Lnp(t, v). In the next section we provide a Monte Carlo
procedure to obtain each cjα.
Theorem 2 establishes that each Uˆnpj is consistent against its alternative.
Theorem 2. In addition to the conditions given in Theorem 1, assume that λ1(t, v) and λ2(t, v)
are continuous and that H(t, v) > 0 on [0, τ ] × [0, 1]. Then, P (Uˆnp1 > c1α) → 1 as n → ∞
under H1, and P (Uˆnp2 > c2α) → 1 as n →∞ under H2.
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Theorems 1 and 2 also hold for Lspn and Uˆ
sp
j , j = 1, 2, under the same conditions except
that the conditions on λk(t) are replaced by the proportional marginal hazards assumption λ1(t)/
λ2(t) = exp(β). Theorem 1 holds for L1n under the same conditions minus any assumptions
about λk(t). We note that the tests Uˆ1j are not consistent tests since they are based on L1n(τ, v) —
by integrating over t ∈ [0, τ ], differences between the two mark-specifi c hazard functions may
cancel in a case that the marginal hazards cross. Consistent supremum versions of these statistics
are easily constructed, however. By accumulating the contrast at the end of follow-up τ, the tests
based on Uˆ1j presented here may be more powerful than their supremum counterparts, in cases
that the marginal hazards do not strongly cross.
3.2 Gaussian Multipliers Simulation Procedure
We now describe a Gaussian multipliers technique for simulating each of the test processes
Lnpn (t, v),
Lspn (t, v), and L1n(t, v) under the null hypothesis, cf. Lin, Wei and Ying (1993). Note that
γk(ds, v)/yk(s) =
∫ v
0
λk(s, u) duds. By (8.2) in the Appendix and the continuous mapping
theorem, we obtain the result that
∫ t
a
y−1k (s)
√
nk(Nk(ds, v)− Yk(s)Λk(ds, v))
=
∫ t
a
y−1k (s)
√
nk(Nk(ds, v)/nk − γk(ds, v))−
∫ t
a
y−2k (s)
√
nk(Yk(s)/nk − yk(s)) γk(ds, v)
D−→Zk(t, v). (3.4)
Defi ne the processL˜np(t, v) by replacing Zk(t, v), k = 1, 2, in Lnp(t, v) given in (3.2) with
the term on the left side of (3.4) and replacing κ with n1/n. Applying the continuous mapping
theorem again, we have L˜np(t, v) D−→Lnp(t, v). Let Nki(t, v) = I(Xki ≤ t, δki = 1, Vki ≤ v) and
Yki(t) = I(Xki ≥ t), k = 1, 2. It follows that
L˜np(t, v) =
√
n2/nn1
−1/2
n1∑
i=1
h1i(t, v)−
√
n1/nn2
−1/2
n2∑
i=1
h2i(t, v); (3.5)
h1i(t, v) =
∫ t
a
H(s)y−11 (s) (N1i(ds, v)− Y1i(s)Λ1(ds, v))
−
∫ t
a
H(s)a(s)Λ′2s(s, v)y
−1
1 (s) (N1i(ds, 1)− Y1i(s)Λ1(ds, 1))
10
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h2i(t, v) =
∫ t
a
H(s)r(s)y−12 (s) (N2i(ds, v)− Y2i(s)Λ2(ds, v))
−
∫ t
a
H(s)b(s)Λ′2s(s, v)y
−1
2 (s) (N2i(ds, 1)− Y2i(s)Λ2(ds, 1))
with a(s) = 1/λ2(s), b(s) = λ1(s)/(λ2(s))2, and Λ′2s(s, v) = ∂Λ2(s, v)/∂s.
Defi nehˆki(t, v) by replacing, in hki(t, v), H(s) with Hn(s), yk(s) with Yk(s)/nk, a(s) with
aˆ(s), and Λ′2s(s, v) with a suitable smooth uniformly consistent estimate Λˆ′2s(s, v) on [a, τ ]×[0, 1].
Let Wki, i = 1, . . . , nk, k = 1, 2, be i.i.d. standard normal random variables. Let
Lnp∗n (t, v) =
√
n2
n
n1
−1/2
n1∑
i=1
hˆ1i(t, v)W1i −
√
n1
n
n2
−1/2
n2∑
i=1
hˆ2i(t, v)W2i. (3.6)
We show that the conditional weak limit of the process Lnp∗n (t, v) given the observed data is
the same as the weak limit of Lnpn (t, v) under the null hypothesis H0. Note that the two terms
in (3.2) and (3.6) are independent. It is easy to show that for any two points (t, v) and (s, w) in
[a, τ ]× [0, 1], n−1k
∑nk
i=1 hˆ1i(t, v)hˆ1i(s, w)
P−→E[h1i(t, v)h1i(s, w)], since hˆki(t, v) P−→hki(t, v) as
n →∞. Thus, the conditional covariance of Lnp∗n (t, v) converges to the covariance of Lnp(t, v).
It is left to show that the process Lnp∗n (t, v) is tight (see Appendix).
Theorem 3. Under the conditions of Theorem 1, conditional on the observed data, Lnp∗n (t, v) D−→
Lnp(t, v) in D([a, τ ]× [0, 1]) under H0 as n →∞, where Lnp(t, v) is given in (3.2).
Theorem 3 also holds for the semiparametric tests of H0, using the following modifi ed test
processes. By the proof of Proposition 1, under H0
Lspn (t, v) =
√
n2
n
∫ t
0
Hn(s)Zˆ1(ds, v)−
√
n1
n
∫ t
0
Hn(s) exp(βˆ)Zˆ2(ds, v)
−
√
n1n2
n
∫ t
0
Hn(s)[exp(βˆ)− exp(β)]Λ2(ds, v). (3.7)
Let Un(β) and Jn(β) be the score function and information matrix under the proportional
marginal hazards model. It is easy to obtain that
Un(β) =
n1∑
i=1
∫ τ
0
∑n2
j=1 Y2j(s)∑n1
j=1 Y1j(s) exp(β) +
∑n2
j=1 Y2j(s)
N1i(ds, 1)
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−
n2∑
i=1
∫ τ
0
∑n1
j=1 Y1j(s) exp(β)∑n1
j=1 Y1j(s) exp(β) +
∑n2
j=1 Y2j(s)
N2i(ds, 1)
≡
n1∑
i=1
U1i(β)−
n2∑
i=1
U2i(β);
Jn(β) =
2∑
k=1
nk∑
i=1
∫ τ
0
∑n1
j=1 Y1j(s)
∑n2
j=1 Y2j(s) exp(β)
(
∑n1
j=1 Y1j(s) exp(β) +
∑n2
j=1 Y2j(s))
2
Nki(ds, 1).
A routine delta method and likelihood analysis yields n1/2(exp(βˆ)−exp(β)) = exp(β)(n−1Jn(β))−1n−1/2
Un(β)+op(1). From this result and (3.7), following the arguments of Section 3.2, the distribution
of Lspn (t, v) under H0 can be approximated by the following process Lsp∗n (t, v) given the observed
data,
Lsp∗n (t, v) =
√
n2
n
n1
−1/2
n1∑
i=1
[ ∫ t
0
Hn(s)(n1Y
−1
1 (s)) (N1i(ds, v)− Y1i(s)Λ1(ds, v))
−n1
n
exp(βˆ)(n−1Jn(βˆ))
−1Uˆ1i(βˆ)
∫ t
0
Hn(s)Λˆ2(ds, v)
]
W1i
−
√
n1
n
n2
−1/2
n2∑
i=1
[ ∫ t
0
Hn(s) exp(βˆ)(n2Y
−1
2 (s)) (N2i(ds, v)− Y2i(s)Λ2(ds, v))
−n2
n
exp(βˆ)(n−1Jn(βˆ))
−1Uˆ2i(βˆ)
∫ t
0
Hn(s)Λˆ2(ds, v)
]
W2i,
where Uˆ1i(βˆ) and Uˆ2i(βˆ) are obtained from U1i(β) and U2i(β), respectively, with β, Λ1(ds, 1)
and Λ2(ds, 1) replaced by βˆ, Λˆ1(ds, 1) and Λˆ2(ds, 1), respectively.
Similarly, the distribution of L1n(t, v) under H00 can be approximated by L1∗n (t, v) given the
observed data, where
L1∗n (t, v) =
√
n1
n
n2
−1/2
n2∑
i=1
∫ t
0
Hn(s)(n2Y
−1
2 (s)) (N2i(ds, v)− Y2i(s)Λ2(ds, v))W2i
−
√
n2
n
n1
−1/2
n1∑
i=1
∫ t
0
Hn(s)(n1Y
−1
1 (s)) (N1i(ds, v)− Y1i(s)Λ1(ds, v))W1i.
3.3 Choice of Weight Process and a Graphical Procedure
In exploratory work it can be useful to examine a plot of the test process Lrn(t, v) with the weight
process chosen to be Hn(t) = 1, and compare it with plots of (say) 5–20 realizations of the
12
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simulated reference process Lr∗n (t, v). Large values of |L1(t, v)| for some v and t suggest a
departure from H00 . Large values of Lnpn (t1, v) − Lnpn (t2, v) for some v and some t1 < t2, as
compared with the same contrast in Lnp∗n (t, v), suggest a departure from H0 in the direction
of H1. Large absolute differences in Lnpn (t, v) across different marks v (as compared with the
reference process) would suggest H2. This graphical procedure is illustrated in Section 6.
The test process is more variable at larger failure times, so it is advisable to choose the weight
process to downweight the upper tail of the integral, and we suggest
Hn(s) =
√
Y1(s)
n1
Y2(s)
n2
. (3.8)
The weight can also be chosen to increase power against specifi c alternatives (Sun, 2001).
4 ESTIMATION OF MARK-SPECIFIC VACCINE EFFICACY
Precise estimation of VE(t, v) introduced in Section 1 requires huge sample sizes, because
smoothing is required in both v and t, and generally effi cacy trials do not provide suffi cient
samples (Gilbert et al., 2002). Accordingly, we consider an alternative notion of mark-specifi c
vaccine effi cacy defi ned in terms of cumulative incidences:
VEc(t, v) = 1− F1(t, v)/F2(t, v),
which we call cumulative vaccine effi cacy. This represents a time-averaged — rather than instan-
taneous — measure of vaccine effi cacy and is much easier to estimate than VE(t, v). We also
consider the doubly cumulative vaccine effi cacy
VEdc(t, v) = 1− P (T1 ≤ t, V1 ≤ v)/P (T2 ≤ t, V2 ≤ v),
which can be estimated without smoothing and with greater precision than VEc(t, v).
A nonparametric estimator of VEc(t, v) is given by V̂E
c
(t, v) = 1− Fˆ1(t, v)/Fˆ2(t, v), where
Fˆk(t, v) =
1
bk
∫ 1
0
∫ t
0
Sˆk(s−)
Yk(s)
K
(
v − u
bk
)
Nk(ds, du), (4.1)
13
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Sˆk(t) is the Kaplan–Meier estimate of Sk(t), K(·) is a bounded symmetric kernel function with
support [−1, 1] and integral 1, and bk > 0 is a bandwidth. The estimator Fˆk(t, v) is the continuous
analog of the estimator that has been used for a discrete mark (Prentice et al., 1978).
If F1(t, v) 6= 0 and F2(t, v) 6= 0, a 100(1− α)% pointwise confi dence interval for VEc(t, v)
can be computed by transforming symmetric confi dence limits about log(F1(t, v)/F2(t, v)) :
1−
(
1− V̂Ec(t, v)
)
exp
±zα/2
√
V̂ar{Fˆ1(t, v)}
Fˆ1(t, v)2
+
V̂ar{Fˆ2(t, v)}
Fˆ2(t, v)2
 ; (4.2)
V̂ar{Fˆk(t, v)} = 1
b2k
∫ 1
0
∫ t
0
[
Sˆk(s−)
Yk(s)
K
(
v − u
bk
)]2
Nk(ds, du).
To estimate VEdc(t, v), each P (Tk ≤ t, Vk ≤ v) is simply estimated by Fˆk1(t) =
∫ t
0
(
Sˆk(s−)/Yk(s)
)
Nk(ds, v), the estimator for the cumulative incidence function for cause of failure defi ned by
V ≤ v, and its variance is estimated by ∫ t
0
(
Sˆk(s−)/Yk(s)
)2
Nk(ds, v).
5 SIMULATION EXPERIMENT
The simulations are based on the features of the VaxGen trial described in the Introduction. We
study performance of the test statistics Uˆ1j , j = 1, 2, 3, 4; Uˆ
np
j and Uˆ
sp
j , j = 1, 2; and of V̂E
c
(τ, v),
with τ = 3 years. For VEc(τ, v) we focus on the end of follow-up t = τ because it is most
important scientifi cally to understand durability of vaccine effi cacy.
The main simulations were done with Tk and Vk independent, k = 1, 2, wherein the cumula-
tive incidence function for group k is Fk(t, v) = P{Tk ≤ t}fV k(v), where fV k is the density of
Vk. In the fi rst set of simulations we specify T1 and T2 to be exponential with parameters θλ2 and
λ2, respectively, so that the cumulative vaccine effi cacy by time τ irrespective of the mark V is
given by VEc(τ) = 1− (1− exp(−λ2θτ))/(1− exp(−λ2τ)), where λ2 is the constant infection
hazard rate in the placebo group. Here θ is the constant infection hazard ratio between groups
1 and 2. In the second set of simulations we specify non-proportional hazards, wherein Vk and
T2 are distributed the same as above, and T1 is set as T1 =
√
X1, where X1 is exponential with
parameter λ1, implying λ1(t) = 2λ1t.
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We consider two true values of VEc(τ), 0.67 and 0.33. To evaluate the size of the tests of H 00
we also consider VEc(τ) = 0.0. We select λ2 so that 50% of placebo recipients are expected to
be infected by τ = 36 months.
Next, we specify
fV k(v) =
[
βk
(
1.51/βk − 0.51/βk)]−1 (v + 0.5)(1/βk)−1 for 0 ≤ v ≤ 1.
Here βk = 1 corresponds to λk(t, v) not depending on v, with E(Vk) = 1/2, and βk = 0.5, 0.25
correspond to increasing levels of dependence between λk(t, v) and v, with E(Vk) = 2/3 and 4/5,
respectively. The cumulative vaccine effi cacy is given by
VEc(τ, v) = 1− (1− VEc(τ)) β2
β1
[
1.51/β2 − 0.51/β2
1.51/β1 − 0.51/β1
]
(v + 0.5)(1/β1)−(1/β2) .
Note that VE(τ, v) = VE(τ) and VEc(τ, v) = VEc(τ) if and only if β1 = β2, so that setting
β2/β1 = 1.0 represents H0. Furthermore β2/β1 > 1 implies VE(τ, v) and VEc(τ, v) decrease
with v, so the extent of departure from H0 increases with β2/β1. We set the true (β1, β2) to be
(1.0, 1.0), (0.50, 1.0), (0.25, 1.0), (0.50, 0.50), or (0.25, 0.25). We also consider a two-sided
alternative with fV 2(v) a uniform density and fV 1(v) = 163 vI(v <
1
2
) + (8
3
− 8
3
v)I(v ≥ 1
2
).
Results for this case are given under the heading “2-sided” in Tables 1-3.
The weight process Hn(·) of (3.8) is used for the test statistics. For kernel estimation of
λk(t), k = 1, 2, the Epanechnikov kernel K(x) = 0.75(1 − x2)I(|x| ≤ 1) is used. For each
simulation iteration the optimal bandwidth bk is chosen to minimize an asymptotic approximation
to the mean integrated squared error of λˆk (Andersen et al., 1993, p. 240) separately for k = 1, 2,
and the method of Gasser and Mu¨ller (1979) is used to correct for bias in the tails. An alternative
approach would jointly optimize (b1, b2) for estimating the hazard ratio. Based on Kelsall and
Diggle (1995), joint optimization does not provide appreciable effi ciency gains unless the hazards
in the two groups are fairly similar. For the HIV vaccine application, it is most interesting to
assess the relationship of vaccine effi cacy on viral divergence when there is some effi cacy (i.e.,
the hazards are unequal), because (tautologically) some degree of protection is necessary for there
to be differential protection. For this reason we optimized bk for the hazard functions separately.
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The nominal level of the tests is set at 0.05, and critical values are calculated using 500 repli-
cates of the Gaussian multipliers technique described in Section 3.2. For estimation, the mark-
bandwidths bvk were chosen to achieve reasonably smooth estimates, which was accomplished
with bv1 = bv2 = 0.20. Bias, coverage probability of the 95% confi dence intervals (4.2), and
variance estimation of V̂E
c
(τ, v) are evaluated at the three mark-values v = 0.30, 0.50, 0.80. We
choose n = 100, 200 or 400 and in addition to the 50% administrative censoring for the failure
times at 36 months we use a 10% random censoring rate in each arm. The performance statistics
are calculated based on 1000 simulated datasets.
The results in Table 1 indicate that the tests of H00 have appropriate sizes and high powers.
When V E(t, v) declines with v, they have greater power than the Cox model Wald test of V E =
0. Therefore accounting for the mark variable can substantially improve effi ciency. This is
especially the case for Uˆ12 , although this test has less power than the Cox model test if V E(t, v)
is constant in v (i.e., β1 = β2). In contrast, the power of Uˆ11 is less sensitive to how strongly
V E(t, v) varies in v. The corresponding 2-sided tests Uˆ13 and Uˆ14 show a similar comparative
pattern but with lower power for the one-sided alternatives.
The results in Table 2 show that the tests of H0 perform well at moderate sample sizes.
Somewhat surprisingly, for small/moderate samples the semiparametric tests did not provide
greater power than the nonparametric tests in the case that the failure times had proportional
hazards. To explain this, note that the nonparametric and semiparametric test processes involve
contrasts Λˆ1(dt, v) − rˆ(t)Λˆ2(dt, v), with rˆ(t) = λˆ1(t)/λˆ2(t) and exp(βˆ), respectively, and the
alternative hypothesis involves changes of λ1(t, v)/λ2(t, v) in v— but not in t. Since Λˆk(dt, v)
and λˆk(t) approximately “track” each other in t, the nonparametric test process can reduce the
noise from perturbations of λˆ1(t)/λˆ2(t) in t, whereas the semiparametric test process cannot
dampen this noise.
The small simulation study under non-proportional hazards, with H0 true with (β1, β2) =
(1.0,1.0), (0.5,0.5), or (0.25,0.25), demonstrates (as predicted from the theory) that the semi-
parametric tests are not valid when the marginal proportional hazards condition is not met. The
empirical sizes of the tests frequently missed 0.05 by an amount more than 2 or 3 Monte Carlo
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standard deviations (results not shown).
The results in Table 3 show that for moderate samples V̂E
c
(36, v) is unbiased at some param-
eter confi gurations and biased at others, and that the bias becomes negligible as the number of
infections grows large. The confi dence intervals for VEc(36, v) have correct coverage probability
in large samples and usually perform well at smaller sample sizes, but have too-small coverage
probability for the same values of VEc(36, v) at which the estimator is substantially negatively
biased. The asymptotic variance estimates of V̂E
c
(36, v) tracked the Monte Carlo variance esti-
mates fairly closely, verifying acceptable accuracy of the variance estimators (not shown).
Additional simulations were conducted with Tk and Vk dependent for both groups, and the
test procedures showed nominal size, and power was not eroded. The simulation study was
programmed in Fortran, with pseudorandom-numbers generated with internal Fortran functions.
This program and a data analysis program are available upon request.
6 APPLICATION
We apply the methods to the data from the VaxGen trial described in the Introduction. Figure 1
shows boxplots of the three percent amino acid mismatch distances of the infecting HIV viruses
to the nearest virus (MN or GNE8) represented in the tested vaccine. The testing procedures
were implemented using the same weight function Hn(·), kernel K(·), and procedures for opti-
mal bandwidth selection and tail correction that were used in the simulation experiment. P-values
were approximated using 10,000 simulations. The MISE-optimized bandwidths bk for the esti-
mated hazards of infection λˆ1(·) and λˆ2(·) were b1 = 1.83 months and b2 = 2.10 months. For
the neutralizing face core distances, the four tests of H 00 : VE(t, v) = 0 gave p-values spanning
0.05 to 0.32 (Figure 1(d)), with Uˆ12 rejecting H00 at level 0.05. Based on this evidence (albeit
weak) that VE(t, v) 6= 0, we go on to test H0 : VE(t, v) = VE(t). Neither nonparametric test
rejected H0 (Figure 1(d)). The proportional hazards assumption seemed reasonable based on a
goodness-of-fi t test (p = 0.35), justifying the semiparametric tests of H0, which gave nonsignif-
icant results (Figure 1(d)). To illustrate the graphical procedure, Figure 2 shows the test process
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Lnpn (t, v) together with 8 randomly selected realization of the null test process Lnp∗n (t, v), using a
unit weight process Hn(·) = 1. The maximum absolute deviation of Lnpn (t, v) in t is larger than
that for all but one of the null test processes. Figures 1(e)-(f) show p-values of the tests for the
other two distances, which all exceeded 0.05.
With bandwidths bv1 and bv2 separately optimized using 2-fold cross-validation, we next es-
timated VEc(36, v) and VEdc(36, v) (Figure 3). The VEc(36, v) curves are estimated with rea-
sonable precision at mark values v not in the tail regions, and VEdc(36, v) is estimated with
reasonable precision for v not in the left tail, with precision increasing with v. For neutralizing
face core distances the estimates of VEc(36, v) and VEdc(36, v) in the regions of precision di-
minished with viral distance, which suggests that the closeness of match of amino acids in the
exposing strain versus vaccine strain in the core amino acids may have impacted the ability of
the vaccine to stimulate protective antibodies that neutralized the exposing strain. The border-
line signifi cant result is intriguing, because this distance has the soundest biological rationale–
three-dimensional structural analysis has demonstrated that the amino acid positions used for this
distance constitute conserved neutralizing antibody epitopes (Wyatt et al., 1998).
7 CONCLUDING REMARKS
Nonparametric and semiparametric methods have been developed for testing and estimation of
relative risks taking into account a continuous mark variable observed only at uncensored failure
times, and for evaluating the relationship between the relative risk and the mark. We showed
that if the mark-specifi c relative risk varies with the mark, then a standard Cox model test of a
unit hazard ratio (ignoring the mark) is less powerful (and sometimes much less) than the newly
developed nonparametric procedures that test the null H 00 : λ1(t, v)/λ2(t, v) = 1 of a unit mark-
specifi c hazard ratio. This fi nding raises the novel idea to consider accounting for the mark
variable in primary hypothesis tests in clinical trials for which there are strong reasons to suspect
that the mark-specifi c relative risk is monotone in the mark. Among the statistics developed for
testing H00 , Uˆ11 or Uˆ12 are recommended, with the choice between them depending on how strongly
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the mark-specifi c relative risk varies with the mark in the alternative hypothesis of interest.
For testing dependency of the mark-specifi c relative risk on the mark, H0 : λ1(t, v)/λ2(t, v) =
λ1(t)/λ2(t), the simulations suggest that the nonparametric procedures perform better than their
semiparametric counterparts that assume proportional marginal hazards. The test based on Uˆnp1
is recommended.
Although the methods were motivated by a particular scientifi c problem (the question in HIV
vaccine effi cacy trials of if and how effi cacy of the tested vaccine varies with the genetic distance
of the infecting HIV strain), we emphasize that they provide a general solution to the two-sample
survival analysis problem with a continuous mark variable, which may have many applications.
An appeal of the procedures developed here is that they are based on a mark-specifi c version of
the widely-applied and well-understood Nelson–Aalen-type nonparametric maximum likelihood
estimator, and naturally extend the scope of methods that have been developed for competing
risks data with discrete (cause-of-failure) marks.
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8 APPENDIX: PROOFS OF THEOREMS
Proofs of the results in Section 3.2 are presented for the nonparametric tests of H0, involving
Lnpn (t, v) and Uˆ
np
j with r(t) = λ1(t)/λ2(t). The proofs are similar and simpler for the other tests
and are omitted.
Proposition 1. Given the conditions expressed in Theorem 1,
Lnpn (t, v)−
√
n1n2
n
∫ t
a
Hn(s)[Λ1(ds, v)− r(s)Λ2(ds, v)] D−→Lnp(t, v) (8.1)
in D([a, τ ]× [0, 1]).
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Proof of Proposition 1.
Using the central limit theorem for empirical processes (cf. Gilbert, McKeague and Sun,
2004, (A.4)),
√
nk(Nk(t, v)/nk − γk(t, v), Yk(t)/nk − yk(t)) D−→(G(k)1 (t, v), G(k)2 (t)) (8.2)
in D([0, τ ] × [0, 1]) × D[0, τ ], where G(k)1 (t, v) and G(k)2 (t) are continuous mean zero Gaussian
processes with covariances
Cov(G
(k)
1 (s, u), G
(k)
1 (t, v)) = γk(s ∧ t, u ∧ v)− γk(s, u)γk(t, v),
Cov(G
(k)
2 (s), G
(k)
2 (t)) = yk(s ∨ t)− yk(s)yk(t),
Cov(G
(k)
1 (s, u), G
(k)
2 (t)) = (γk(s, u)− γk(t−, u))I(t ≤ s)− γk(s, u)yk(t).
Let Zˆk(t, v) =
√
nk(Λˆk(t, v)− Λk(t, v)). By the functional delta method as used in (A.7)–(A.8)
of Gilbert et al. (2001), we have
Zˆk(t, v)
D−→Zk(t, v) (8.3)
in D([0, τ ] × [0, 1]), where the two processes Z1(t, v) and Z2(t, v) are independent. Applying
the almost sure representation theorem (Shorack and Wellner, 1986, p. 47) as in the proof of
Proposition 2 of Gilbert, McKeague and Sun (2004), we may treat the weak convergence in (8.3)
as almost sure convergence uniformly on [0, τ ]× [0, 1].
The test process can be decomposed as follows:
Lnpn (t, v) =
√
n1n2
n
∫ t
a
Hn(s)[Λˆ1(ds, v)− Λ1(ds, v)]
−
√
n1n2
n
∫ t
a
Hn(s)rˆ(s)[Λˆ2(ds, v)− Λ2(ds, v)] +
√
n1n2
n
∫ t
a
Hn(s)[Λ1(ds, v)− rˆ(s)Λ2(ds, v)]
=
√
n2
n
∫ t
a
Hn(s)Zˆ1(ds, v)−
√
n1
n
∫ t
a
Hn(s)rˆ(s)Zˆ2(ds, v)
+
√
n1n2
n
∫ t
a
Hn(s)[r(s)− rˆ(s)]Λ2(ds, v) +
√
n1n2
n
∫ t
a
Hn(s)[Λ1(ds, v)− r(s)Λ2(ds, v)].(8.4)
Under H0, the last term equals zero. Let aˆ(s) = 1/λˆ2(s) and bˆ(s) = λ1(s)/(λ2(s)λˆ2(s)). Let
a(s) = 1/λ2(s) and b(s) = λ1(s)/(λ2(s))2. The third term of (8.4) equals√
n1n2
n
∫ t
a
Hn(s)[−aˆ(s)(λˆ1(s)− λ1(s)) + bˆ(s)(λˆ2(s)− λ2(s))]Λ2(ds, v). (8.5)
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Next, the third term in (8.4) can be approximated by the integrations with respect to Zˆk(t, 1),
k = 1, 2. Note that
λˆk(t) =
1
bk
∫ τ+δ
0
K
(
t− s
bk
)
dΛˆk(s)
and
1
bk
∫ τ+δ
0
K
(
t− s
bk
)
dΛk(s) = λk(t) +
1
2
b2kλ
′′
k(t)
∫ 1
−1
x2K(x) dx + O(b3k),
uniformly in t ∈ [a, τ ]. We have, by changing the order of integration and noting the compact
support of the kernel function K(·) on [−1, 1],√
n1n2
n
∫ t
a
Hn(s)aˆ(s)(λˆ1(s)− λ1(s))Λ2(ds, v) (8.6)
=
√
n1n2
n
∫ τ+δ
0
[∫ t
a
1
b1
K
(
s− u
b1
)
Hn(s)aˆ(s)Λ2(ds, v)
]
d(Λˆ1(u)− Λ1(u)) + O(
√
nb31)
=
√
n1n2
n
∫ t−b1
a−b1
[∫ t
a
1
b1
K
(
s− u
b1
)
Hn(s)aˆ(s)Λ2(ds, v)
]
d(Λˆ1(u)− Λ1(u))
+
√
n1n2
n
∫ t+b1
t−b1
[∫ t
a
1
b1
K
(
s− u
b1
)
Hn(s)aˆ(s)Λ2(ds, v)
]
d(Λˆ1(u)− Λ1(u)) + O(
√
nb31).
By the uniform convergence of Hn(s) to H(s) and aˆ(s) to a(s), and the uniform continuity of
H(s) and a(s), we have
1
b1
∫ t
a
K
(
s− u
b1
)
Hn(s)aˆ(s)Λ2(ds, v) = H(u)a(u)Λ
′
2u(u, v) + op(1),
uniformly in u ∈ (a − b1, t + b1), 0 ≤ t ≤ τ , where Λ′2u(u, v) = ∂Λ2(u, v)/∂u. Further, the
process
∫ t
a
b−11 K((s − u)/b1)Hn(s)aˆ(s)Λ2(ds, v) is of bounded variation in u uniformly in n,
v ∈ [0, 1] and t ∈ [0, τ ], and H(u)a(u)Λ′2u(u, v) is of bounded variation uniformly in v ∈ [0, 1].
It follows from Lemma A.1 of Lin and Ying (2001) that (8.6) equals√
n1n2
n
∫ t−b1
a−b1
H(u)a(u)Λ′2u(u, v) d(Λˆ1(u)− Λ1(u)) + O(
√
nb31) + O(b1)
=
√
n2
n
∫ t
a
H(s)a(s)Λ′2s(s, v) Zˆ1(ds, 1) + O(
√
nb31) + op(1). (8.7)
Similarly, √
n1n2
n
∫ t
a
Hn(s)bˆ(s)(λˆ2(s)− λ2(s))Λ2(ds, v)
=
√
n1
n
∫ t
a
H(s)b(s)Λ′2s(s, v) dZˆ2(ds, 1) + O(
√
nb32) + op(1). (8.8)
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By (8.4), (8.6), (8.7) and (8.8), under √nb3k → 0, as n →∞ for k = 1, 2, we have
Lnpn (t, v) =
√
n2
n
[∫ t
a
Hn(s)Zˆ1(ds, v)−
∫ t
a
H(s)a(s)Λ′2s(s, v) Zˆ1(ds, 1)
]
−
√
n1
n
[∫ t
a
Hn(s)rˆ(s)Zˆ2(ds, v)−
∫ t
a
H(s)b(s)Λ′2s(s, v) dZˆ2(ds, 1)
]
+
√
n1n2
n
∫ t
a
Hn(s)[Λ1(ds, v)− r(s)Λ2(ds, v)] + op(1).
By Lemma 1 in Bilias, Gu and Ying (1997), we have
Lnpn (t, v) =
√
n2
n
[∫ t
a
H(s)Zˆ1(ds, v)−
∫ t
a
H(s)a(s)Λ′2s(s, v) Zˆ1(ds, 1)
]
−
√
n1
n
[∫ t
a
H(s)r(s)Zˆ2(ds, v)−
∫ t
a
H(s)b(s)Λ′2s(s, v) dZˆ2(ds, 1)
]
+
√
n1n2
n
∫ t
a
Hn(s)[Λ1(ds, v)− r(s)Λ2(ds, v)] + op(1).
Note that b(s) = r(s)a(s). It follows by the continuous mapping theorem that
Lnpn (t, v)−
√
n1n2
n
∫ t
a
Hn(s)[Λ1(ds, v)− r(s)Λ2(ds, v)] D−→Lnp(t, v).
in D([a, τ ]× [0, 1]).
Proof of Theorem 2.
Under H1, the ratio λ1(t, v)/λ2(t, v) increases with v for all t ∈ [0, τ ]. Since λk(t) =∫ 1
0
λk(t, v) dv, k = 1, 2, and under H1,
λ1(t, 0)
λ2(t, 0)
≤ λ1(t, v)
λ2(t, v)
≤ λ1(t, 1)
λ2(t, 1)
,
we have
λ1(t, 0)
λ2(t, 0)
≤ λ1(t)
λ2(t)
≤ λ1(t, 1)
λ2(t, 1)
.
Under the assumptions of Theorem 2, λ1(t,v)
λ2(t,v)
is continuous in v ∈ [0, 1] for every t ∈ [0, τ ]. By
the intermediate-value theorem, for every t ∈ [0, τ ] there exists a vt ∈ [0, 1] such that
r(t) =
λ1(t)
λ2(t)
=
λ1(t, vt)
λ2(t, vt)
.
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We choose vt to be the smallest v satisfying this equality. It follows that vt is a continuous
function of t and
λ1(t, v)
λ2(t, v)
≤ r(t) for v ≤ vt and λ1(t, v)
λ2(t, v)
≥ r(t) for v ≥ vt.
Note that the inequality in H1 is strict for some (t, v), λk(t) =
∫ 1
0
λk(t, v) dv and the functions
λ1(t, v) and λ2(t, v) are continuous. There exists an open neighborhood of t such that 0 < vt < 1.
Let a > 0 and s1 < s2 be such that vt − a, vt + a ∈ (0, 1) for t ∈ [s1, s2]. Then∫ vt+a
vt
H(t)(λ1(t, v)− r(t)λ2(t, v)) dv −
∫ vt
vt−a
H(t)(λ1(t, v)− r(t)λ2(t, v)) dv > 0,
for t ∈ [s1, s2]. Since the integrals above are uniform continuous functions of (t, vt) and vt is
uniform continuous, there exists a neighborhood [t1, t2] ⊂ [s1, s2] and [v1, v2] ⊂ [0, 1] such that∫ t2
t1
∫ v2
v1+v2
2
H(s)(λ1(s, v)−r(s)λ2(s, v)) dv ds−
∫ t2
t1
∫ v1+v2
2
v1
H(s)(λ1(s, v)−r(s)λ2(s, v)) dv ds ≥ c > 0,
where c is a constant. Let δn(t1, t2, v1, v2) be the left side of the above expression with H(s) re-
placed by Hn(s). Since Hn(t)
P−→H(t) > 0 uniformly in t ∈ [0, τ ], we have √n1n2
n
δn(t1, t2, v1, v2)
P−→∞,
as n →∞. By Proposition 1,
∆rn(t2, v1, v2)−∆rn(t1, v1, v2)−
√
n1n2
n
δn(t1, t2, v1, v2)
=
[
(Lrn(t2, v2)− Lrn(t1, v2))− (Lrn(t2,
v1 + v2
2
)− Lrn(t1,
v1 + v2
2
))
]
−
[
(Lrn(t2,
v1 + v2
2
)− Lrn(t1,
v1 + v2
2
))− (Lrn(t2, v1)− Lrn(t1, v1))
]
−
√
n1n2
n
δn(t1, t2, v1, v2)
D−→
[
(Lr(t2, v2)− Lr(t1, v2))− (Lr(t2, v1 + v2
2
)− Lr(t1, v1 + v2
2
))
]
−
[
(Lr(t2,
v1 + v2
2
)− Lr(t1, v1 + v2
2
))− (Lr(t2, v1)− Lr(t1, v1))
]
(8.9)
Applying Slusky’s Theorem, we have Uˆ r1
P−→∞ as n →∞.
We note that, under H2, there exist [t1, t2] and [v1, v2] such that∣∣∣∣∣
∫ t2
t1
∫ v2
v1+v2
2
H(s)(λ1(s, v)− r(s)λ2(s, v)) dv ds−
∫ t2
t1
∫ v1+v2
2
v1
H(s)(λ1(s, v)− r(s)λ2(s, v)) dv ds
∣∣∣∣∣ ≥ c > 0.
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Otherwise, H(s)(λ1(s, v) − r(s)λ2(s, v)) is a constant function of (s, v), which would be zero
since λk(t) =
∫ 1
0
λk(t, v) dv, k = 1, 2. Since Hn(t)
P−→H(t) > 0 uniformly in t ∈ [0, τ ], it
follows that
√
n1n2
n
|δn(t1, t2, v1, v2)| P−→∞, as n → ∞. By (8.9) and Slutsky’s Theorem, we
have Uˆ r2
P−→∞ as n →∞. This completes the proof.
Proof of the tightness for Lnp∗n (t, v) (remaining piece of the proof of Theorem 3).
To show tightness of Lnp∗n (t, v) given the observed data sequence, it suffi ces to check a slight
extension of the moment conditions of Bickel and Wichura (1971) for stochastic processes on
the plane, cf. McKeague and Zhang’s (1994, page 506) extension of the moment conditions of
Billingsley (1968).
It is suffi cient to show that n1−1/2
∑n1
i=1 hˆ1i(t, v)W1i in (3.6) is tight given the observed data
sequence. The tightness of the second term follows similarly. Let B = [t1, t2]× [v1, v2] and G =
[s1, s2]× [x1, x2] be any pair of neighboring blocks in [0, τ ]× [0, 1]. Let hˆ1i(B) = hˆ1i(t2, v2)−
hˆ1i(t2, v1)− hˆ1i(t1, v2) + hˆ1i(t1, v1) and
∆(B) = n
−1/2
1
n1∑
i=1
hˆ1i(B)W1i.
We show that there exists a fi nite measure µ0 on [0, τ ]× [0, 1] such that
E
{
∆2(B)
∣∣∣{observed data}} ≤ µ0(B) + op(1) (8.10)
E
{
∆2(B)∆2(G)
∣∣∣{observed data}} ≤ µ0(B)µ0(G) + op(1), (8.11)
where the op(1) term converges to zero in probability independently of (or uniformly in) B and
G. Since a simple linear combination of tight processes is tight, it suffi ces to check the conditions
(8.10) and (8.11) for each of the four terms in hˆ1i. However, for ease of notation we use hˆ1i to
represent any one of the four terms.
By the uniform convergence of Hn(s), Yk(s), Nk(s, v)/nk, aˆ(s), and Λˆ′2s(s, v) on [a, τ ] ×
[0, 1], a simple probability argument yields that
E
{
∆2(B)
∣∣∣{observed data}} ≤ n−11 n1∑
i=1
(hˆ1i(B))
2 + op(1) (8.12)
E
{
∆2(B)∆2(G)
∣∣∣{observed data}} ≤ 6n−21 n1∑
i=1
(hˆ1i(B))
2
n1∑
i=1
(hˆ1i(G))
2 + op(1)(8.13)
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Then (8.10) and (8.11) follow from working with each of the four terms of hˆ1i in (8.12) and
(8.13). The details are omitted.
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Table 1. Empirical Power (× 100%) for Testing H01 and H02
VE(τ) = 0 VE(τ) = 0.33 VE(τ) = 0.67
β1 β1 β1
nk Test Altern. 1 1 0.5 0.25 2-sided 1 0.5 0.25 2-sided
100 Cox1 5.2 65.1 65.1 65.1 61.8 99.9 99.9 99.9 99.8
(48)2 Uˆ11 H01 7.9 68.1 72.3 78.8 58.7 99.8 1.0 1.0 96.8
Uˆ12 H
0
1 7.7 58.5 81.0 97.8 56.5 97.8 1.0 1.0 97.7
Uˆ13 H
0
2 5.9 55.4 60.2 69.7 47.3 98.9 99.5 1.0 94.8
Uˆ14 H
0
2 6.7 47.6 71.8 94.8 43.1 96.8 99.3 1.0 94.6
200 Cox 5.0 90.6 90.6 90.6 1.0 1.0 1.0 1.0 1.0
(95)2 Uˆ11 H01 5.0 92.7 94.3 97.2 91.5 1.0 1.0 1.0 1.0
Uˆ12 H
0
1 5.3 86.0 98.4 1.0 88.1 1.0 1.0 1.0 1.0
Uˆ13 H
0
2 7.0 87.5 90.3 94.7 84.7 1.0 1.0 1.0 1.0
Uˆ14 H
0
2 5.3 81.0 95.4 1.0 79.4 1.0 1.0 1.0 1.0
400 Cox 5.8 99.7 99.7 99.7 1.0 1.0 1.0 1.0 1.0
(190)2 Uˆ11 H01 6.6 99.9 99.9 1.0 99.5 1.0 1.0 1.0 1.0
Uˆ12 H
0
1 6.0 99.0 1.0 1.0 98.8 1.0 1.0 1.0 1.0
Uˆ13 H
0
2 5.3 99.6 99.9 1.0 99.0 1.0 1.0 1.0 1.0
Uˆ14 H
0
2 5.2 97.9 1.0 1.0 97.6 1.0 1.0 1.0 1.0
1Test statistic is a Wald Z-statistic based on the standard Cox model that ignores the mark.
2Average number of subjects infected in group 2 (placebo).
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Table 2. Empirical Power (× 100%) for Testing H1 and H2
VE(τ) = 0.33 VE(τ) = 0.67
β1 β1
nk Test Altern. 1 0.5 0.25 2-sided 1 0.5 0.25 2-sided
100 Uˆnp1 H1 6.4 21.8 59.0 42.7 7.1 17.0 35.2 22.9
(48)1 Uˆnp2 H2 6.2 15.9 47.7 43.3 6.7 12.2 26.1 20.4
Uˆ
sp
1 H1 6.2 18.3 52.9 35.8 5.7 12.8 30.2 17.8
Uˆ
sp
2 H2 4.4 11.1 41.4 38.8 3.5 7.3 18.7 15.3
200 Uˆnp1 H1 6.3 32.4 87.0 78.3 6.7 21.0 62.7 48.8
(95)1 Uˆnp2 H2 6.8 23.0 81.4 80.9 6.5 14.3 54.2 51.4
Uˆ
sp
1 H1 5.6 29.7 84.8 76.8 5.5 20.0 61.1 46.3
Uˆ
sp
2 H2 5.4 20.8 79.5 81.4 4.8 13.2 49.6 45.6
400 Uˆnp1 H1 5.8 48.2 99.5 98.3 6.2 33.7 93.3 87.4
(190)1 Uˆnp2 H2 5.2 35.8 98.6 98.7 5.8 25.4 89.2 90.4
Uˆ
sp
1 H1 5.4 46.7 99.0 98.3 5.5 32.7 92.9 86.1
Uˆ
sp
2 H2 4.8 35.3 98.5 98.7 5.1 23.8 87.9 89.4
1Average number of subjects infected in group 2 (placebo).
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Table 3. Bias of V̂Ec(36, v) and 95% Coverage Probability of VEc(36, v)
VE(τ) = 0.0 VE(τ) = 0.67 VE(τ) = 0.33
β1 β1 β1
nk v 1 1 0.5 0.25 1 0.5 0.25
Average Bias × 100
100 (48)1 0.3 -6.3 −2.3 −6.3 −31.6 −2.5 −5.0 −20.8
0.5 -5.8 −1.3 −2.6 −13.7 −3.6 −3.6 −9.0
0.8 -6.3 −3.7 −3.0 −3.6 −5.2 −5.1 −9.6
200 (95)1 0.3 -2.8 −0.1 −1.6 −13.0 −0.9 −1.6 −9.0
0.5 -1.6 −0.0 −0.9 −4.8 −1.0 −2.2 −6.0
0.8 -3.5 −0.5 −0.6 −1.5 −2.1 −2.7 −5.4
400 (190)1 0.3 -1.4 −0.0 −0.4 −3.7 −0.2 −0.1 −3.0
0.5 -1.1 −0.1 −0.8 −3.6 −0.0 −0.9 −4.6
0.8 -0.8 −0.3 0.1 −0.9 −0.3 −0.2 −2.4
Coverage Probability× 100%
100 (48)1 0.3 97.6 97.9 96.0 73.9 97.2 97.3 86.6
0.5 97.7 98.6 97.5 90.0 97.5 97.9 95.2
0.8 94.7 96.0 96.2 95.4 94.6 94.9 96.1
200 (95)1 0.3 96.7 96.5 96.8 77.1 97.8 97.1 88.0
0.5 97.2 96.7 97.5 93.8 96.8 97.5 96.5
0.8 94.9 94.4 95.3 95.8 94.5 95.6 95.9
400 (190)1 0.3 96.8 95.4 96.4 87.8 96.8 97.3 92.2
0.5 96.4 96.3 95.9 93.6 96.5 97.2 96.4
0.8 96.9 96.0 96.3 96.7 96.2 96.8 96.8
1Average number of subjects infected in group 2 (placebo).
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Figure Captions
Figure 1. For the VaxGen HIV vaccine trial, the top panel of the fi gure shows boxplots of amino
acid Hamming distances in HIV gp120 between the infecting viruses and the nearest vaccine
strain MN or GNE8, for distances computed in (a) the neutralizing face core, (b) the neutralizing
face core plus the V2/V3 loops, and (c) the V3 loop. The bottom panel shows p-values of the
studied tests: Cox corresponds to the Wald test in the Cox model; 11, 12, 13, 14 correspond to
Uˆ11 , Uˆ
1
2 , Uˆ
1
3 , Uˆ
1
4 ; n1, n2, correspond to Uˆ
np
1 , Uˆ
np
2 , ; s1, s2, correspond to Uˆ
sp
1 , Uˆ
sp
2 .
Figure 2. For the VaxGen HIV vaccine trial and neutralizing face core distances, the top-left
panel shows the observed test process Lnpn (t, v) and the other panels show 8 randomly selected
realizations of the simulated null test process Lnp∗n (t, v).
Figure 3. For the VaxGen HIV vaccine trial, the left panels show point and 95% confi dence
interval estimates of VEc(36, v) = 1 − F1(36, v)/F2(36, v) versus the HIV gp120 amino acid
distance between infecting viruses and the nearest vaccine antigen MN or GNE8, for distances
computed in (a) the neutralizing face core, (c) the neutralizing face core plus the V2/V3 loops,
and (e) the V3 loop. The right panels show corresponding point and interval estimates of
VEdc(36, v) = 1 − P (T1 ≤ 36, V1 ≤ v)/P (T2 ≤ 36, V2 ≤ v) for these three distances. The
dashed horizontal line is the overall vaccine effi cacy estimateV̂E
c
(36) = 0.048.
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